Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Angelos Stergiou
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- 2.49
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 190.28
Financials
Revenue
$0.00-100.0%Net Income
$-9.61MEBITDA
$-9.61MFree Cash Flow
$-7.59MEPS (diluted)
$-0.05Shares Outstanding (diluted)
189.18M+745598.1%Operating Expenses
$10.63MCash & Debt
$138.44MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.86M | $-0.25 |
| 2024 | $0.00 | $-30.88M | $-0.50 |
| 2023 | $0.00 | $-37.34M | $-1.34 |
| 2022 | $1.00M | $-41.30M | $-2.13 |
| 2021 | $7.60M | $-20.70M | $-1.34 |
| 2020 | $1.90M | $-16.76M | $-2.11 |
| 2019 | $0.00 | $-19.29M | $-10.92 |
| 2018 | $0.00 | $-27.67M | $-157.72 |
| 2017 | $0.00 | $-23.75M | $-521.91 |
| 2016 | $0.00 | $-23.55M | $-933.13 |
| 2015 | $0.00 | $-63.90M | $-411.55 |
| 2014 | $9.32M | $-36.61M | $-1022.20 |
| 2013 | $2.49M | $-76.68M | $-25500.26 |
| 2012 | $2.04M | $-34.97M | $-1866.21 |
Valuation
SLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·1d ago·Negative
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer - Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SE…
View source ↗ - Newsbenzinga.com·7d ago·Negative
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
View source ↗
Earnings
Wed, Nov 11(in 2 months)
Consensus estimate $-0.05 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.05 vs $-0.04miss
- Tue, May 12$-0.05 vs $-0.06beat
- Thu, Mar 19$-0.05 vs $-0.06beat
- Wed, Nov 12$-0.06 vs $-0.06beat
- Tue, Aug 12$-0.07 vs $-0.08beat
- Tue, May 13$-0.07 vs $-0.10beat
Estimates and results for SLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SLS officers and directors.
- Bought
- $185k
- Sold
- $26k
4 trades
3 trades
- Kalin Katherine Bachbought
- Van Nostrand Robert Lbought
- Wasman Janebought
- Kalin Katherine Bachbought
- Stergiou Angelos M.sold
- Burns John Thomassold
- Wood Barbara Asold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.